[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Teleflex Medical Europe Ltd\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":95},{"warningLetters":4,"total":94},[5,32,55,75],{"id":6,"raw":7,"subject":14,"body_html":15,"body_text":16,"firm_name":17,"letter_id":18,"created_at":19,"fei_number":20,"letter_url":21,"updated_at":22,"action_type":23,"case_status":24,"posted_date":25,"marcs_cms_no":26,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":20,"reference_number":20,"action_taken_date":31,"medical_device_id":20,"response_letter_date":20},1436,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-06-04T04:00:00Z\">06\u002F04\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-12-26T05:00:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechlem-medical-corporation-671395-12262023\">Techlem Medical Corporation\u003C\u002Fa>","Center for Devices and Radiological Health","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded\u003Cbr \u002F>\r\n","","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Anurag Sinha, President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Techlem Medical Corporation\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6890 Pacific Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Mississauga\u003C\u002Fspan> \u003Cspan>ON\u003C\u002Fspan> \u003Cspan>L5T 1N8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Canada\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>December 26, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Sinha,\u003C\u002Fp>\n\n\u003Cp>During an inspection of your firm located in Mississauga, Canada on June 19, 2023, through June 22, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wheeled stretchers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\u003C\u002Fp>\n\n\u003Cp>This inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, \u003Cu>Code of Federal Regulations \u003C\u002Fu>(CFR), Part 820.\u003C\u002Fp>\n\n\u003Cp>We received a response from your firm dated July 17, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1. Failure to adequately establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\u003C\u002Fp>\n\n\u003Cp>a. On June 19, 2023, your President confirmed CAPA procedures have not been established.\u003C\u002Fp>\n\n\u003Cp>b. As a result of your firm’s February 2023 audit, an observation was found that the welding equipment used in the manufacture of the devices needed to be fixed since it was “not penetrating”. The affected parts were replaced as identified on the firm’s Annual Audit Finding document. However, the following could not be provided:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Investigation into how long the welding equipment was not performing adequately,\u003C\u002Fli>\n\t\u003Cli>Testing and the effectiveness of the corrections made to the welding equipment, and\u003C\u002Fli>\n\t\u003Cli>Ensuring the adequacy of the three-month cleaning schedule.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm developed and submitted a CAPA procedure, CA-003 – Corrective and Preventive Action; however, it is deficient in several ways. The following are some, but not all areas of your CAPA procedure that are deficient:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Under Procedure, External Complaints, it states “When an external non-conformance occurs, and when applicable, Techlem Medical Corporation responds in a manner best suited to the customer’s needs.” This statement is ineffective as it gives no specific direction. The procedure should identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems. There is no mention in the CAPA procedure of verifying or validating the corrective and preventive action to ensure that the action is effective and does not adversely affect the finished device.\u003C\u002Fli>\n\t\u003Cli>There is no mention in the CAPA procedure of ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems.\u003C\u002Fli>\n\t\u003Cli>There is no mention in the CAPA procedure of submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>2. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22. For example: You stated that you perform internal quality system audits annually; however, you lacked procedures for the internal quality audits. Your response dated July 17, 2023, is not adequate. Your firm developed and submitted your Internal Audit procedure, IA-007; however, you did not provide evidence of implementation of the newly developed procedure.\u003C\u002Fp>\n\n\u003Cp>3. Failure to establish and maintain a design history file for each type of device, as required by 21 CFR 820.30(j). For example: Your design control procedure as identified in the Quality Manual section Research and Development does not include a requirement to establish and maintain a design history file. You did not establish a design history file and you lacked the requirement to establish and maintain one.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. You submitted your Quality Manual, which under the Research and Development section, on page 10, requires that a design history file be established and maintained by Quality Assurance. However, you did not provide evidence of implementation of this requirement. You also submitted your Design Control Procedure, DC-004; however, the procedure does not address the requirement to establish a design history file.\u003C\u002Fp>\n\n\u003Cp>4. Failure to adequately document acceptance activities to include the signature of the individual conducting the acceptance activities, as required by 21 CFR 820.80(e). For example: On page 23 of your Quality Manual it states, “At conclusion of final inspection, the OC Inspector will sign off on the Inspection Report.” However, 16 final inspection sheets reviewed during the inspection did not have a sign off signature or release date. The adequacy of your response dated July 17, 2023, cannot be determined at this time. You submitted a blank Techlem Medical – Final QC Inspection Sheet, which contains a space for the signature and release date; however, you did not provide evidence of implementation of this revised form.\u003C\u002Fp>\n\n\u003Cp>5. Failure to adequately establish and maintain procedures to ensure that device history records for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record and the requirements of 21 CFR 820, as required by 21 CFR 820.184. For example: The Quality Manual procedure does not define where labeling for the finished devices will be maintained.\u003C\u002Fp>\n\n\u003Cp>The adequacy of your response dated July 17, 2023, cannot be determined at this time. The Quality Manual does not address labeling, but your firm has since developed DHR-016, Device History Record, that addresses where labeling for the finished devices will be maintained. However, you did not provide evidence of implementation of DHR-016, Device History Record.\u003C\u002Fp>\n\n\u003Cp>6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors and consultants, as required by 21 CFR 820.50(a). For example: A Vendor Approval Form is used to gather information about a potential supplier. This form requires three references to confirm the status of the potential supplier. The procedure, Purchasing-Vendor Approval section of the Quality Manual does not include this requirement of three references. Thus, the procedure does not adequately establish and maintain the requirements used to evaluate and select potential suppliers. For example, by stating how many good references are needed for approval of the supplier.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. You submitted your revised Quality Manual and a new purchasing SOP, POR-011 – Supplier Approval. In addition, you submitted a Supplier Approval Checklist.. Your purchasing SOP, POR-011 – Supplier Approval, appears to contain all the information stipulated under 21 CFR 820.50, Purchasing Controls. However, the requirements used to evaluate and select potential suppliers are still unclear. Neither the revised Quality Manual, the new Supplier Approval SOP, nor the Supplier Approval Checklist contain a requirement of three references to qualify a supplier and it is unknown whether the Approved\u002FPreferred Vendor Application Form containing the three-reference requirement is still being used or if it was superseded by one of the new documents submitted. Additionally, you did not submit evidence of implementation and you did not indicate whether you will conduct a retrospective review of your existing suppliers to determine if the suppliers have met the defined requirements.\u003C\u002Fp>\n\n\u003Cp>7. Failure to adequately establish procedures to control document changes, as required by 21 CFR 820.40(b). For example: Several of your revised documents lack a revision number, a release signature of the approving individual(s), and a date of approval.\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm lacked document control procedures and therefore, developed and submitted COR-002 – Control of Records. A portion of the purpose statement of this document is as follows: “To ensure the documents are Reviewed, Approved, Updated, and distributed and stored in a controlled manner.” However, the document does not address document approval, nor does it address document changes.\u003C\u002Fp>\n\n\u003Cp>Our inspection also revealed that your firm’s wheeled stretchers are misbranded within the meaning of section 502(t)(2) [21 U.S.C. § 352(t)(2)], in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. And 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Techlem Medical Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\u003C\u002Fp>\n\n\u003Cp>The failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21. U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S. C. § 331(q)(1)(B).\u003C\u002Fp>\n\n\u003Cp>Your response dated July 17, 2023, is not adequate. Your firm submitted evidence that you have obtained UDIs; however, a search of the GUDID database on October 17, 2023, did not reveal any entries.\u003C\u002Fp>\n\n\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993.&nbsp;\u003Cstrong>Refer to CMS case #671395 when replying\u003C\u002Fstrong>. If you have any questions about the contents of this letter, please contact: David Wolloscheck at 301-796-1480.\u003C\u002Fp>\n\n\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nCourtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT 3: Office of GastroRenal, ObGyn,\u003Cbr>\n&nbsp; &nbsp;General Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nDr. Anurag Sinha, President\n\nRecipient Title\n\nCEO\n\nTechlem Medical Corporation\n\n6890 Pacific Circle\n\nMississauga ON L5T 1N8\n\nCanada\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDecember 26, 2023\n\nDear Dr. Sinha,\n\nDuring an inspection of your firm located in Mississauga, Canada on June 19, 2023, through June 22, 2023, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures wheeled stretchers. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or function of the body.\n\nThis inspection revealed that these devices are adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, their manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820.\n\nWe received a response from your firm dated July 17, 2023, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, which was issued to your firm. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n\n1. Failure to adequately establish procedures for implementing corrective and preventive action, as required by 21 CFR 820.100(a). For example:\n\na. On June 19, 2023, your President confirmed CAPA procedures have not been established.\n\nb. As a result of your firm’s February 2023 audit, an observation was found that the welding equipment used in the manufacture of the devices needed to be fixed since it was “not penetrating”. The affected parts were replaced as identified on the firm’s Annual Audit Finding document. However, the following could not be provided:\n\nInvestigation into how long the welding equipment was not performing adequately,\n\nTesting and the effectiveness of the corrections made to the welding equipment, and\n\nEnsuring the adequacy of the three-month cleaning schedule.\n\nYour response dated July 17, 2023, is not adequate. Your firm developed and submitted a CAPA procedure, CA-003 – Corrective and Preventive Action; however, it is deficient in several ways. The following are some, but not all areas of your CAPA procedure that are deficient:\n\nUnder Procedure, External Complaints, it states “When an external non-conformance occurs, and when applicable, Techlem Medical Corporation responds in a manner best suited to the customer’s needs.” This statement is ineffective as it gives no specific direction. The procedure should identify the action(s) needed to correct and prevent recurrence of nonconforming product and other quality problems. There is no mention in the CAPA procedure of verifying or validating the corrective and preventive action to ensure that the action is effective and does not adversely affect the finished device.\n\nThere is no mention in the CAPA procedure of ensuring that information related to quality problems or nonconforming product is disseminated to those directly responsible for assuring the quality of such product or the prevention of such problems.\n\nThere is no mention in the CAPA procedure of submitting relevant information on identified quality problems, as well as corrective and preventive actions, for management review.\n\n2. Failure to adequately establish procedures for quality audits, as required by 21 CFR 820.22. For example: You stated that you perform internal quality system audits annually; however, you lacked procedures for the internal quality audits. Your response dated July 17, 2023, is not adequate. Your firm developed and submitted your Internal Audit procedure, IA-007; however, you did not provide evidence of implementation of the newly developed procedure.\n\n3. Failure to establish and maintain a design history file for each type of device, as required by 21 CFR 820.30(j). For example: Your design control procedure as identified in the Quality Manual section Research and Development does not include a requirement to establish and maintain a design history file. You did not establish a design history file and you lacked the requirement to establish and maintain one.\n\nYour response dated July 17, 2023, is not adequate. You submitted your Quality Manual, which under the Research and Development section, on page 10, requires that a design history file be established and maintained by Quality Assurance. However, you did not provide evidence of implementation of this requirement. You also submitted your Design Control Procedure, DC-004; however, the procedure does not address the requirement to establish a design history file.\n\n4. Failure to adequately document acceptance activities to include the signature of the individual conducting the acceptance activities, as required by 21 CFR 820.80(e). For example: On page 23 of your Quality Manual it states, “At conclusion of final inspection, the OC Inspector will sign off on the Inspection Report.” However, 16 final inspection sheets reviewed during the inspection did not have a sign off signature or release date. The adequacy of your response dated July 17, 2023, cannot be determined at this time. You submitted a blank Techlem Medical – Final QC Inspection Sheet, which contains a space for the signature and release date; however, you did not provide evidence of implementation of this revised form.\n\n5. Failure to adequately establish and maintain procedures to ensure that device history records for each batch, lot, or unit are maintained to demonstrate that the device is manufactured in accordance with the device master record and the requirements of 21 CFR 820, as required by 21 CFR 820.184. For example: The Quality Manual procedure does not define where labeling for the finished devices will be maintained.\n\nThe adequacy of your response dated July 17, 2023, cannot be determined at this time. The Quality Manual does not address labeling, but your firm has since developed DHR-016, Device History Record, that addresses where labeling for the finished devices will be maintained. However, you did not provide evidence of implementation of DHR-016, Device History Record.\n\n6. Failure to adequately establish and maintain the requirements, including quality requirements, that must be met by suppliers, contractors and consultants, as required by 21 CFR 820.50(a). For example: A Vendor Approval Form is used to gather information about a potential supplier. This form requires three references to confirm the status of the potential supplier. The procedure, Purchasing-Vendor Approval section of the Quality Manual does not include this requirement of three references. Thus, the procedure does not adequately establish and maintain the requirements used to evaluate and select potential suppliers. For example, by stating how many good references are needed for approval of the supplier.\n\nYour response dated July 17, 2023, is not adequate. You submitted your revised Quality Manual and a new purchasing SOP, POR-011 – Supplier Approval. In addition, you submitted a Supplier Approval Checklist.. Your purchasing SOP, POR-011 – Supplier Approval, appears to contain all the information stipulated under 21 CFR 820.50, Purchasing Controls. However, the requirements used to evaluate and select potential suppliers are still unclear. Neither the revised Quality Manual, the new Supplier Approval SOP, nor the Supplier Approval Checklist contain a requirement of three references to qualify a supplier and it is unknown whether the Approved\u002FPreferred Vendor Application Form containing the three-reference requirement is still being used or if it was superseded by one of the new documents submitted. Additionally, you did not submit evidence of implementation and you did not indicate whether you will conduct a retrospective review of your existing suppliers to determine if the suppliers have met the defined requirements.\n\n7. Failure to adequately establish procedures to control document changes, as required by 21 CFR 820.40(b). For example: Several of your revised documents lack a revision number, a release signature of the approving individual(s), and a date of approval.\n\nYour response dated July 17, 2023, is not adequate. Your firm lacked document control procedures and therefore, developed and submitted COR-002 – Control of Records. A portion of the purpose statement of this document is as follows: “To ensure the documents are Reviewed, Approved, Updated, and distributed and stored in a controlled manner.” However, the document does not address document approval, nor does it address document changes.\n\nOur inspection also revealed that your firm’s wheeled stretchers are misbranded within the meaning of section 502(t)(2) [21 U.S.C. § 352(t)(2)], in that there was a failure or refusal to furnish any material or information required by or under section 519 of the Act, 21 U.S.C. § 360i, respecting these devices. In particular, 21 CFR 801.20(a) requires, with exceptions not relevant here, that the label and device package of every medical device bear a unique device identifier (UDI) that meets the requirements of 21 CFR Part 801, subpart B, and 21 CFR Part 830. And 21 CFR 830.300(a) and 830.320(b) – both of which were promulgated under section 519 of the Act, among other provisions – require that the labeler of a device submit electronically to FDA’s Global Unique Device Identification Database (GUDID) the information required by 21 CFR Part 830, subpart E, for each version or model required to bear a UDI. FDA has determined that your firm causes a label to be applied to a device with the intent that the device will be commercially distributed without any subsequent replacement or modification of the label. Techlem Medical Corporation is therefore a “labeler” within the meaning of 21 CFR 830.3, and has not submitted to GUDID any information required by 21 CFR Part 830, subpart E, respecting these devices.\n\nThe failure or refusal to furnish any notification or other material or information required by or under section 519 of the Act, 21. U.S.C. § 360i, also constitutes a prohibited act under section 301(q)(1)(B) of the Act, 21 U.S. C. § 331(q)(1)(B).\n\nYour response dated July 17, 2023, is not adequate. Your firm submitted evidence that you have obtained UDIs; however, a search of the GUDID database on October 17, 2023, did not reveal any entries.\n\nOther federal agencies may take your compliance with the FD&C Act and its implementation regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed.\n\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, including an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective action (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Please provide a translation of documentation not in English to facilitate our review. We will notify you regarding the adequacy of your firm’s response(s) and the need to re-inspect your firm’s facility to verify that the appropriate corrections and\u002For corrective actions have been made. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2, FDA Regulatory Inspections and Audits Team, White Oak Building 66, 10903 New Hampshire Ave., Silver Spring, MD 20993. Refer to CMS case #671395 when replying. If you have any questions about the contents of this letter, please contact: David Wolloscheck at 301-796-1480.\n\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT 3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health","Techlem Medical Corporation","techlem-medical-corporation-671395-12262023","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftechlem-medical-corporation-671395-12262023","2026-10-26T08:10:10.30362+00:00","Warning Letter","Issued","2024-06-04","671395","Medical Devices","Dr. Anurag Sinha, President","2026-08-20T00:03:33.008+00:00","VIA UNITED PARCEL SERVICE","2023-12-26",{"id":33,"raw":34,"subject":39,"body_html":40,"body_text":41,"firm_name":42,"letter_id":43,"created_at":44,"fei_number":20,"letter_url":45,"updated_at":46,"action_type":23,"case_status":24,"posted_date":47,"marcs_cms_no":48,"product_type":49,"closeout_date":20,"issuing_office":38,"recipient_name":50,"body_fetched_at":51,"delivery_method":52,"recipient_title":20,"reference_number":53,"action_taken_date":54,"medical_device_id":20,"response_letter_date":20},21927,[35,36,37,38,39,13,13,13],"\u003Ctime datetime=\"2026-10-20T04:00:00Z\">10\u002F20\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-06T04:00:00Z\">10\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026\">Tides Medical LLC\u003C\u002Fa>","Center for Biologics Evaluation and Research (CBER)","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>CBER 26-727246\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Joe Spell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Chief Executive Officer \u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Tides Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>605 Kaliste Saloom Road, Suite 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Lafayette\u003C\u002Fspan>, \u003Cspan>LA\u003C\u002Fspan> \u003Cspan>70508\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:jspell@tidesmedical.com\"> jspell@tidesmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Biologics Evaluation and Research (CBER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>October 6, 2026\u003C\u002Fp>\u003Cp>CBER 26-727246\u003C\u002Fp>\u003Cp>Dear Mr. Spell:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003Cem>\u003Cstrong>\u003Csup>1\u003C\u002Fsup>\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fp>\u003Cp>FDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\u003Cp>Your firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\u003C\u002Fp>\u003Cul>\u003Cli>“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\u003C\u002Fli>\u003Cli>“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Because there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\u003C\u002Fp>\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Our office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Please notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Send your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\u003C\u002Fp>\u003Cp>Sincerely,\u003C\u002Fp>\u003Cp>\u002FS\u002F\u003C\u002Fp>\u003Cp>Vincent Amatrudo\u003Cbr>Acting Director\u003Cbr>Office of Compliance and Biologics Quality\u003Cbr>Center for Biologics Evaluation and Research\u003C\u002Fp>\u003Cp>___________________\u003C\u002Fp>\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nCBER 26-727246\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nJoe Spell\n\nRecipient Title\n\nChief Executive Officer\n\nTides Medical LLC\n\n605 Kaliste Saloom Road, Suite 1\n\nLafayette, LA 70508\n\nUnited States\n\njspell@tidesmedical.com\n\nIssuing Office:\n\nCenter for Biologics Evaluation and Research (CBER)\n\nUnited States\n\nWARNING LETTER\nOctober 6, 2026\nCBER 26-727246\nDear Mr. Spell:\nThe United States Food and Drug Administration (FDA) has learned that your firm is distributing APLICOR 3D in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act). Under section 201(h) of the Act, 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.1\nFDA has reviewed information and records, including your website at https:\u002F\u002Fwww.tidesmedical.com\u002Faplicor-3d\u002F (last visited October 2026), and determined that APLICOR 3D is adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) for these devices in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). APLICOR 3D is also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not timely notify the agency of its intent to begin the introduction or delivery for introduction into interstate commerce for commercial distribution of these devices, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\nYour firm has stated that the APLICOR 3D device is a Class I device exempt from the requirement of premarket notification. You have indicated that the APLICOR 3D device is a liquid medication dispenser under product code KYX and 21 CFR 880.6430. Devices classified under 21 CFR 880.6430, liquid medication dispenser, are exempt from premarket notification unless they exceed the limitations of exemptions at 21 CFR 880.9. However, there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, liquid medication dispenser. 21 CFR 880.6430(a) states that a liquid medication dispenser is a device intended for medical purposes that is used to issue a measured amount of liquid medication. However, your firm is distributing APLICOR 3D for the following intended uses:\n“APLICOR 3D is a hyper-personalized 3D bioprinting platform that uses a patient’s own adipose tissue to create customized grafts for acute and chronic wounds. With a single application, this system simplifies workflows and accelerates wound progression.”\n“APLICOR 3D is a single-use 3D bioprinting system that transforms autologous adipose tissue into a personalized graft, precisely matching the size and depth of a patient’s wound.”\n“APLICOR 3D is designed for use in treating acute and chronic wounds such as diabetic foot ulcers, venous stasis ulcers, pressure injuries, burns, and trauma.”\nBecause there is evidence that APLICOR 3D is intended for uses that are different from those of legally marketed devices classified under 21 CFR 880.6430, it exceeds the limitations described in 21 CFR 880.9 and is not exempt from premarket notification.\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before FDA. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. FDA will evaluate the information that your firm submits and decide whether the products may be legally marketed.\nConclusion\nOur office requests that Tides Medical LLC cease any activities that result in the misbranding or adulteration of APLICOR 3D, including the commercial distribution of these devices for the uses discussed above.\nYour firm should take prompt action to address any violations identified in this letter. Failure to promptly and adequately address this matter may result in regulatory action being initiated by FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nPlease notify our office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions your firm has taken, which should address any systemic problems. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen (15) business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that APLICOR 3D is not in violation of the Act, include your reasoning and any supporting information for our consideration as part of your response.\nSend your electronic response and any questions regarding this letter to CBER’s Office of Compliance and Biologics Quality, Division of Case Management at CBERDCMRecommendations@fda.hhs.gov. Refer to the CBER number at the top of this letter when replying.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm. It is your firm’s responsibility to ensure compliance with the applicable laws and regulations administered by FDA.\nSincerely,\n\u002FS\u002F\nVincent Amatrudo\nActing Director\nOffice of Compliance and Biologics Quality\nCenter for Biologics Evaluation and Research\n___________________\n1 FDA acknowledges receipt of your February 26, 2026, correspondence responding to the February 25, 2026, letter sent to your firm from FDA’s Center for Devices and Radiological Health.","Tides Medical LLC","tides-medical-llc-727246-10062026","2026-10-27T01:18:54.544251+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftides-medical-llc-727246-10062026","2026-11-17T01:02:03.701861+00:00","2026-10-20","727246","Biologics","Joe Spell","2026-10-27T01:19:42.766+00:00","VIA UPS and Electronic Mail","CBER 26-727246","2026-10-06",{"id":56,"raw":57,"subject":61,"body_html":62,"body_text":63,"firm_name":64,"letter_id":65,"created_at":66,"fei_number":20,"letter_url":67,"updated_at":68,"action_type":23,"case_status":24,"posted_date":69,"marcs_cms_no":70,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":71,"body_fetched_at":72,"delivery_method":73,"recipient_title":20,"reference_number":20,"action_taken_date":74,"medical_device_id":20,"response_letter_date":20},434,[58,59,60,11,61,13,13,13],"\u003Ctime datetime=\"2025-12-09T05:00:00Z\">12\u002F09\u002F2025\u003C\u002Ftime>\n","\u003Ctime datetime=\"2025-11-11T05:00:00Z\">11\u002F11\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025\">Envoy Medical Inc.\u003C\u002Fa>","CGMP\u002FQSR\u002FMedical Devices\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Brent T. Lucas\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>CEO &amp; Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Envoy Medical Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4875 White Bear Parkway\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55110-3325\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:blucas@envoymedical.com\"> blucas@envoymedical.com \u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\u003Cstrong>CMS # 718762\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>November 11, 2025\u003C\u002Fp>\u003Cp>Dear Mr. Lucas:\u003C\u002Fp>\u003Cp>During an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Quality System Regulation Violation(s)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>This inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\u003C\u002Fp>\u003Cp>1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\u003C\u002Fp>\u003Cp>Specifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\u003C\u002Fp>\u003Cp>a) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\u003C\u002Fp>\u003Cp>b) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\u003C\u002Fp>\u003Cp>c) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\u003C\u002Fp>\u003Cp>2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\u003C\u002Fp>\u003Cp>Specifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment &amp; CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\u003C\u002Fp>\u003Cp>a) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\u003C\u002Fp>\u003Cp>b) Your firm opened CAPA-00708 on July 10, 2024, for high \u003Cstrong>(b)(4)\u003C\u002Fstrong> particulate counts discovered during \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> at location \u003Cstrong>(b)(4)\u003C\u002Fstrong> in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\u003C\u002Fp>\u003Cp>3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\u003C\u002Fp>\u003Cp>Specifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\u003C\u002Fp>\u003Cp>a) CAPA CA-00701 identified that \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong> used in assembly processes may have incomplete \u003Cstrong>(b)(4)\u003C\u002Fstrong> due to \u003Cstrong>(b)(4)\u003C\u002Fstrong> excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\u003C\u002Fp>\u003Cp>b) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>, while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity \u003Cstrong>(b)(4)\u003C\u002Fstrong>. According to your firm’s Risk Management Process procedure, severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates temporary health problems requiring routine medical care, while severity \u003Cstrong>(b)(4)\u003C\u002Fstrong> indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\u003C\u002Fp>\u003Cp>c) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your \u003Cstrong>(b)(4) \u003C\u002Fstrong>water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\u003C\u002Fp>\u003Cp>The response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as \u003Cstrong>(b)(4)\u003C\u002Fstrong> effects on \u003Cstrong>(b)(4)\u003C\u002Fstrong> for nearly a \u003Cstrong>(b)(4)\u003C\u002Fstrong>, or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add \u003Cstrong>(b)(4)\u003C\u002Fstrong> risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\u003C\u002Fp>\u003Cp>Your firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\u003C\u002Fp>\u003Cp>Other federal agencies may take your compliance with the FD&amp;C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\u003C\u002Fp>\u003Cp>Please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration as part of your response.\u003C\u002Fp>\u003Cp>Your firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Finally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Barbara C. Marsden\u003Cbr>Acting Director\u003Cbr>Office of Regulatory Programs\u003Cbr>Office of Product Evaluation and Quality\u003Cbr>Center for Devices and Radiological Health\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nBrent T. Lucas\n\nRecipient Title\n\nCEO & Director\n\nEnvoy Medical Inc.\n\n4875 White Bear Parkway\n\nSaint Paul, MN 55110-3325\n\nUnited States\n\nblucas@envoymedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\nCMS # 718762\nNovember 11, 2025\nDear Mr. Lucas:\nDuring an inspection of your firm located in Saint Paul, MN from June 24, 2025, through July 2, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufacturers the Esteem II Implantable Hearing System. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), this product is a device because it is intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body.\nQuality System Regulation Violation(s)\nThis inspection revealed that this device is adulterated within the meaning of section 501(h) of the Act, 21 U.S.C. § 351(h), in that the methods used in, or the facilities or controls used for, its manufacture, packing, storage, or installation are not in conformity with the current good manufacturing practice requirements of the Quality System regulation found at Title 21, Code of Federal Regulations (CFR), Part 820. We received your response dated July 22, 2025, from Maksim Trofimovich, Quality Manager, concerning our investigator’s observations noted on the Form FDA 483 (FDA 483), List of Inspectional Observations, that was issued to you. We address this response below, in relation to each of the noted violations. These violations include, but are not limited to, the following:\n1. Failure to adequately establish and maintain procedures for receiving, reviewing, and evaluating complaints by a formally designated unit, as required by 21 CFR 820.198(a).\nSpecifically, your firm has not adequately implemented your Complaint Handling, Medical Device Reporting and Vigilance Reporting, Document Number 000978, Revision 26, Dated 20-May-2024, to ensure complaints are processed in a uniform and timely manner. For example:\na) On November 25, 2024, your firm received Complaint CR-03201 documenting explantation of an Esteem II System due to patient infection. The physical device was received on December 5, 2024, and the incident was reported as a serious injury Medical Device Report (MDR) on December 18, 2024. As of the inspection's conclusion on July 2, 2025, approximately seven months after initial complaint receipt, the investigation remained incomplete. Your firm's complaint procedure (Document 000978) does not include specific requirements for uniform and timely complaint processing. In addition, your firm maintains a procedure for returned product analysis (Document 001005, Revision 12, dated May 20, 2024) that outlines specific failure mode analysis requirements and analytical methods. However, your firm did not conduct and document an investigation for Complaint CR-03201 in accordance with these established protocols as of the conclusion of the July 2025 inspection.\nb) Your firm received Complaint CR-03042 on September 28, 2023, involving sudden battery depletion of the Esteem II System. Your firm determined this complaint to be a significant high-risk event and reported it as a serious injury on April 12, 2024, or approximately seven months after the initial complaint receipt. The device was received for investigation on June 26, 2024. Documentation for Complaint CR-03042 shows that Complaint File Review (CFR) meetings in September 2024 and October 2024 did not determine which engineering team member would be assigned to conduct the required engineering investigation, with the decision deferred further to the November 2024 CFR meeting. At the time of the inspection ending July 2, 2025, this complaint remained pending an engineering review as required by your firm's complaint procedures. No progress updates beyond October 2024 are documented in the complaint record.\nc) Your firm received Complaint CR-03165 on August 22, 2024, involving an Esteem II Transducer that was causing feedback and difficulty programming the Esteem II System, which led to revision surgery to replace the sensor. The device was received for investigation on February 4, 2025, and the incident was reported as a serious injury Medical Device Report (MDR) on February 14, 2025. Your Quality Engineer indicated the device investigation is incomplete pending calibration of inspection equipment required for returned product analysis, however, similar calibrated equipment used in production could potentially be utilized for the returned product analysis but was not employed. At the time of the inspection ending July 2, 2025, this complaint remained open and pending testing as required by the firm's complaint procedures. No progress updates beyond January 2025 are documented in the complaint record.\nThe response dated July 22, 2025, is not adequate. Your firm’s response includes a revised SOP 000978 \"Complaint Handling, Medical Device Reporting and Vigilance Reporting\" (Attachment D - redlined version) which represents a proposed changes rather than an approved, implemented procedure. Concerning timeliness requirements outlined in the procedure, that complaint investigations be completed within 6 months of the first aware date, this may be considered lengthy for addressing regulatory compliance issues. Your firm’s response also includes documentation to demonstrate closure of CR-03201 and CR-03165, but only a progress report for CR-03042 was provided rather than the complete updated complaint record. This suggests CR-03042 remains open pending completion of the ongoing engineering investigation. Your firm’s response indicates your firm’s intent to complete all open complaints by September 2025. However, we have received no updated response(s) from your firm for September\u002FOctober 2025 to demonstrate the investigation completion of CR-03042 and its closure. In addition, your response acknowledges resource diversion to other work priorities but doesn't provide specific safeguards to ensure adequate resources for complaint investigations going forward.\n2. Failure to adequately establish and maintain procedures for corrective and preventive action, as required by 21 CFR 820.100(a).\nSpecifically, your firm's CAPA procedures, Corrective and Preventive Actions, Document Number 000422, Revision 17, Dated September 20, 2024; Quality Event Risk Assessment & CAPA Escalation, Document Number 006411, Revision 03, Dated May 15, 2024; and CAPA Work Instruction, Document Number 006342, Revision 08, Dated September 20, 2024, have not been adequately implemented concerning two critical CAPAs involving high particulate counts in your firm’s ISO Class 8 Cleanrooms. For example:\na) Your firm opened CAPA-00684 on March 2, 2022, following the discovery of high (b)(4) particulate counts during (b)(4) cleanroom monitoring conducted on February 16, 2022. The monitoring, performed by a third-party service identified particulate counts of (b)(4) at location (b)(4) in your large cleanroom, which exceeded the ISO Class 8 requirement of below 3,520,000 particulates\u002Fm³. No Health Hazard Evaluation (HHE), Document 006330, was conducted to assess the potential adverse impact to user safety, including assessment of any impact to products manufactured between February 16, 2022, and May 19, 2022, for the extended period of non-conforming cleanroom conditions.\nb) Your firm opened CAPA-00708 on July 10, 2024, for high (b)(4) particulate counts discovered during (b)(4) cleanroom monitoring conducted on May 8, 2024. The third-party monitoring service found particulate counts of (b)(4) at location (b)(4) and (b)(4) at location (b)(4) in your large cleanroom, both exceeding ISO Class 8 specifications. No HHE was conducted and no further assessment of any impact to products manufactured between February 27, 2024, and October 14, 2024, for the extended period of non-conforming manufacturing conditions.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00712 that addresses the immediate product impact issues both CA-00684 and CA-00708 failed to evaluate. However, CAPA CA-00712 does not provide for an investigation to correct the underlying CAPA system deficiencies that allowed a fundamental failure in risk assessment to occur. Specifically, why qualified personnel conducting CA-00684, and the subsequent CAPA CA-00708, failed to recognize nonconforming conditions, assess the competency or decision-making factors that led to inadequate risk assessment, or updates to underlying CAPA procedures (Documents 000422, 006411, 006342) that allowed the inadequate evaluation to occur. Our concern remains that there appears to be ongoing systemic issues in your CAPA process that CA-00712 does not specifically address.\n3. Failure to adequately establish and maintain design validation procedures to ensure proper risk analysis is completed, as required by 21 CFR 820.30(g).\nSpecifically, your firm's implementation of your primary risk assessment procedure \"Risk Management Process\", Document Number 001000, Revision 11, dated April 17, 2025, did not ensure routine updating of hazard evaluation documentation and the consistent assessment of infection-related risks. For example:\na) CAPA CA-00701 identified that (b)(4) of (b)(4) used in assembly processes may have incomplete (b)(4) due to (b)(4) excursions in your firm’s large ISO Class 8 cleanroom. However, the risk documentation for the Esteem II Sound Processors which includes Esteem II System HA, Document Number 003682, Revision 12, dated April 20, 2017, and Esteem II FMECA, Document Number 006411, Revision 12, dated April 20, 2017, do not include the hazard identified from CA-00701, to evaluate the risk and its potential effects on the Esteem II System.\nb) Your firm's risk assessment does not consistently evaluate infection risks for the Esteem II System. Your risk analysis document establishes three contamination events that lead to the same outcome of patient infection but are assigned different severity ratings. \"Insufficient flow of filtered air\" and \"Contaminated (b)(4) water system\" resulting in \"Excessive contamination or bioburden on parts\" are rated as severity (b)(4), while the \"Contamination not removed from assembly\" with \"Infection or reaction\" is rated as severity (b)(4). According to your firm’s Risk Management Process procedure, severity (b)(4) indicates temporary health problems requiring routine medical care, while severity (b)(4) indicates life-threatening consequences. It is unclear why these three contamination sources that could all lead to patient infection were given different severity ratings when the potential patient harm would be the same.\nc) Your firm's Risk Management Process procedure does not specifically identify endotoxins as a hazard to be considered in the risk management process, and you only perform in-process endotoxin testing of your (b)(4) water system while omitting testing of the finished device, Esteem II System. Your firm maintains no documentation demonstrating that the (b)(4) water system testing is representative of endotoxin risk for the finished device or provides for consideration of other possible sources of endotoxin contamination in your manufacturing process for the device.\nThe response dated July 22, 2025, is not adequate. Your response includes CAPA CA-00716 and identified training deficiencies and procedural gaps as root causes. However, your response does not adequately address why your risk analysis system failed to identify and incorporate critical hazards such as (b)(4) effects on (b)(4) for nearly a (b)(4), or why your risk assessment methodology allowed inconsistent severity ratings for infection-related failure modes that could result in similar patient harm. Your immediate corrections including updating FMECA 003799, to add (b)(4) risks and align infection severity ratings, along with hazard analysis training completed in July 2025. This may address the immediate technical issues but does not demonstrate a comprehensive evaluation of your risk analysis process to ensure all relevant hazards have been identified and properly assessed for your sterile implantable device. Your response also includes CAPA CA-00714 indicating a commitment to implement endotoxin testing for finished devices by September 2025 and update procedure 000500 by August 2025. However, your response does not include any retrospective risk assessment of previously released products that were distributed without endotoxin testing. While your corrective actions focus on procedural documentation improvements including updating procedure 000500 to include endotoxin testing requirements, you do not address updates to procedures including your Risk Management Process (Document 001000), Hazard Analysis (Document 003682), and FMECA (Document 003799), to include endotoxin contamination as an identified critical hazard requiring control for your sterile implantable device.\nYour firm should take prompt action to address any violations identified in this letter. Failure to adequately address this matter may result in regulatory action being initiated by the FDA without further notice. These actions include, but are not limited to, seizure, injunction, and civil money penalties.\nOther federal agencies may take your compliance with the FD&C Act and its implementing regulations into account when considering the award of federal contracts. Additionally, should FDA determine that you have Quality System regulation violations that are reasonably related to premarket approval applications for Class III devices, such devices will not be approved until the violations have been addressed. Should FDA determine that your devices or facilities do not meet the requirements of the Act, requests for Certificates to Foreign Governments (CFG) may not be granted.\nPlease notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of the corrections and\u002For corrective actions (which must address systemic problems) that your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, state the reason for the delay and the time within which these activities will be completed. Your firm’s response should be comprehensive and address any violations included in this Warning Letter. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration as part of your response.\nYour firm’s response should be sent to: Melissa Michurski, Assistant Director, at CDRHEnforcement@fda.hhs.gov. Refer to CMS # 718762 when replying. If you have any questions about the contents of this letter, please contact Salvatore Randazzo, Compliance Officer, at 407-475-4712 or salvatore.randazzo@fda.hhs.gov.\nFinally, you should know that this letter is not intended to be an all-inclusive list of the violations at your firm’s facility. It is your firm’s responsibility to ensure compliance with applicable laws and regulations administered by FDA. The specific violations noted in this letter and in the Inspectional Observations, FDA 483, issued at the close of the inspection may be symptomatic of serious problems in your firm’s manufacturing and quality management systems. Your firm should investigate and determine the causes of any violations and take prompt actions to address any violations and bring the products into compliance.\nSincerely,\n\u002FS\u002F\nBarbara C. Marsden\nActing Director\nOffice of Regulatory Programs\nOffice of Product Evaluation and Quality\nCenter for Devices and Radiological Health","Envoy Medical Inc.","envoy-medical-inc-718762-11112025","2026-08-18T06:42:28.498414+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fenvoy-medical-inc-718762-11112025","2026-10-26T08:08:35.801946+00:00","2025-12-09","718762","Brent T. Lucas","2026-08-19T11:14:00.787+00:00","VIA Electronic Mail","2025-11-11",{"id":76,"raw":77,"subject":81,"body_html":82,"body_text":83,"firm_name":84,"letter_id":85,"created_at":86,"fei_number":20,"letter_url":87,"updated_at":88,"action_type":23,"case_status":24,"posted_date":89,"marcs_cms_no":90,"product_type":27,"closeout_date":20,"issuing_office":11,"recipient_name":91,"body_fetched_at":92,"delivery_method":20,"recipient_title":20,"reference_number":20,"action_taken_date":93,"medical_device_id":20,"response_letter_date":20},3235,[78,79,80,11,81,13,13,13],"\u003Ctime datetime=\"2021-08-03T13:20:00Z\">08\u002F03\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-07-26T04:00:00Z\">07\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021\">Lexion Medical LLC\u003C\u002Fa>","Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Patrick Spearman\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Lexion Medical LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>545 Atwater Circle\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55103\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:pspearman@lexionmedical.com\"> pspearman@lexionmedical.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>July 26, 2021\u003C\u002Fp>\n\n\u003Cp>RE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\u003C\u002Fp>\n\n\u003Cp>Dear Patrick Spearman:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\u003C\u002Fp>\n\n\u003Cp>Under section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&amp;feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>AP 50\u002F30 Insufflator and Insuflow Port\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\u003C\u002Fp>\n\n\u003Cp>For example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\u003C\u002Fp>\n\n\u003Cp>• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\u003Cbr>\n “Less hypothermia”\u003Cbr>\n “Less peritoneal damage”\u003Cbr>\n “Less postoperative pain”\u003Cbr>\n “Decreased amount of pain medication”\u003Cbr>\n “Shortened recovery room stay”\u003Cbr>\n “Less tissue dessication”\u003Cbr>\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\u003C\u002Fp>\n\n\u003Cp>There are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Pneuview XE\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\u003C\u002Fp>\n\n\u003Cp>• “Eliminate \u003Cem>all\u003C\u002Fem> plume, gases, and particles” [emphasis added]\u003Cbr>\n• “…eliminating \u003Cem>all\u003C\u002Fem> harmful contaminants associated with combustion, including viral particles” [emphasis added]\u003Cbr>\n• “actively evacuates and removes \u003Cem>all \u003C\u002Fem>smoke plume including hazardous gas” [emphasis added]\u003Cbr>\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\u003C\u002Fp>\n\n\u003Cp>The cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\u003Cbr>\n\u003Cbr>\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\u003C\u002Fp>\n\n\u003Cp>• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\u003Cbr>\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\u003Cbr>\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\u003Cbr>\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\u003C\u002Fp>\n\n\u003Cp>We are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\u003C\u002Fp>\n\n\u003Cp>Additionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-19\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\u003C\u002Fp>\n\n\u003Cp>• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\u003Cbr>\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\u003Cbr>\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\u003Cbr>\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\u003Cbr>\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\u003Cbr>\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\u003C\u002Fp>\n\n\u003Cp>Taken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\u003C\u002Fp>\n\n\u003Cp>In combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\u003C\u002Fp>\n\n\u003Cp>There is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.\u003Csup>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.\u003Csup>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\u003C\u002Fp>\n\n\u003Cp>For more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\">https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>FDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\">https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products\u003C\u002Fa>. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\u003C\u002Fp>\n\n\u003Cp>For a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\">http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm\u003C\u002Fa>. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\u003C\u002Fp>\n\n\u003Cp>FDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\u003C\u002Fp>\n\n\u003Cp>Your firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\u003C\u002Fp>\n\n\u003Cp>Note, there are two response time frames specified. \u003Cstrong>Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov\u003C\u002Fstrong> describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Please refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Finally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>Sincerely yours,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Courtney H. Lias, Ph.D.\u003Cbr>\nOffice Director\u003Cbr>\nOHT3: Office of GastroRenal, ObGyn,\u003Cbr>\nGeneral Hospital and Urology Devices\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>CC\u003Cbr>\nShelly Amann, Owner\u003Cbr>\nLexion Medical LLC\u003Cbr>\n545 Atwater Circle\u003Cbr>\nSaint Paul, MN 55103\u003Cbr>\nsamann@lexionmedical.com\u003C\u002Fp>\n\n\u003Cp>______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. \u003Cem>J Robot Surg\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>4\u003C\u002Fstrong>\u003C\u002Fem> Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), \u003Cem>available\u003C\u002Fem> at \u003Ca href=\"https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\">https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>5\u003C\u002Fstrong>\u003C\u002Fem> Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at \u003Ca href=\"https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\">https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F\u003C\u002Fa>.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nRecipient Name\n\nPatrick Spearman\n\nRecipient Title\n\nOwner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nUnited States\n\npspearman@lexionmedical.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nJuly 26, 2021\n\nRE: Adulterated and Misbranded Products, including Products Related to Coronavirus Disease 2019 (COVID-19)\n\nDear Patrick Spearman:\n\nThe United States Food and Drug Administration (FDA) has learned that your firm is marketing the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE Gas Evacuation Cannula (Pneuview XE) in the United States without marketing clearance or approval, in violation of the Federal Food, Drug, and Cosmetic Act (the Act).\n\nUnder section 201(h) of the Act, 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. We also note that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-191 in people. As recent as June 22, 2021, FDA reviewed your website, https:\u002F\u002Fwww.lexionmedical.com\u002F and information posted to social media platforms (https:\u002F\u002Ftwitter.com\u002FLexionMedical\u002Fstatus\u002F1245400259888582656, https:\u002F\u002Fwww.youtube.com\u002Fwatch?v=NEhxp1fgewA&feature=emb_logo) and determined that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the devices as described and marketed. The AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are also misbranded under section 502(o) the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). The introduction or delivery for introduction of the product into interstate commerce is prohibited under section 301(a) of the Act, 21 U.S.C. § 331(a). In addition, it is a prohibited act under section 301(k) of the Act, 21 U.S.C. § 331(k), to do any act with respect to a device while the device is held for sale after shipment in interstate commerce and results in the device being misbranded.\n\nAP 50\u002F30 Insufflator and Insuflow Port\n\nThe AP 50\u002F30 Insufflator was cleared under K191780 for use during diagnostic and\u002For therapeutic endoscopic procedures to distend a cavity by filling it with gas. The Insuflow Port was also cleared under K191780 for having applications in thoracic, abdominal and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to heat, humidify, filter and introduce a CO2 gas stream for insufflation of the surgical cavity. However, your firm’s promotion of these devices provides evidence that they are intended for uses such as reduction of cell desiccation, hypothermia, post-operative pain and subcutaneous emphysema, which would constitute major changes or modifications to their intended uses, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing.\n\nFor example, your website, www.Lexion.com, contains the following promotional claims for the AP 50\u002F30 Insufflator and Insuflow Port:\n\n• Under the sections of your website titled, “Gas Delivery” (https:\u002F\u002Fwww.lexionmedical.com\u002Fgas-delivery) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews)\n\n “Less hypothermia”\n\n “Less peritoneal damage”\n\n “Less postoperative pain”\n\n “Decreased amount of pain medication”\n\n “Shortened recovery room stay”\n\n “Less tissue dessication”\n\n• Under the section of your website titled, “Pneumostability” (https:\u002F\u002Fwww.lexionmedical.com\u002Fpneumostability)“reduce the incidence of subcutaneous emphysema”\n\nThere are many factors that may contribute to the health risks listed above. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator and Insuflow Port are effective in the reduction of these risks. Such promotion of your devices for unsupported and uncleared indications, and statements about demonstrating improved safety outcomes, may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to patient harm. If you have data to support these statements, please submit that data to FDA for review. FDA informed your firm in written communications following the submission of 510(k) notifications for a different accessory device that certain claims, such as those listed above, required the submission of clinical data and that literature reviews provided were not adequate to support these indications. The respective submissions were not cleared, were withdrawn, or were cleared without these indications.\n\nPneuview XE\n\nThe Pneuview XE was cleared under K132203 for having applications in thoracic, abdominal, and gynecologic minimally invasive endoscopic surgical procedures to establish a path of entry for endoscopic instruments and to evacuate smoke and plume generated during minimally invasive surgery from the surgical cavity to aid visualization. However, your firm’s promotion of this device provides evidence that it is intended for the elimination of all plume, gases, particles, contaminants, viruses and unsafe negative pressure which would constitute major changes or modifications to its intended use, for which your firm lacks clearance or approval. Any therapeutic, treatment, or prevention effectiveness claims beyond the cleared indication for use constitute a new intended use and requires a premarket submission prior to marketing. For example, the Smoke Evacuation section of your website (https:\u002F\u002Fwww.lexionmedical.com\u002Fsmoke-evacuation) includes the following promotional claims for the Pneuview XE:\n\n• “Eliminate all plume, gases, and particles” [emphasis added]\n\n• “…eliminating all harmful contaminants associated with combustion, including viral particles” [emphasis added]\n\n• “actively evacuates and removes all smoke plume including hazardous gas” [emphasis added]\n\n• “…a patented vacuum break which eliminates the ability of any suction system to pull an unsafe negative pressure on the patient”\n\nThe cleared indication for use of this device includes only evacuation of smoke and plume. FDA is not aware of evidence, and no data have been provided in your 510(k), demonstrating that the Pneuview XE is effective in the removal of all harmful gases, vapors, particulates, or viruses. We note that leakage of gases, vapors, and particulates through the cannula when devices are inserted and removed occurs, regardless of filtration within the system. Therefore, statements including the word “all” or any statements implying 100% removal of vapors, gases, particulates, or viruses are misleading. Misleading claims may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps. Medical practitioners may also overestimate the amount of protection provided them by use of your device in the operating room (OR), which has the potential to lead to patient and practitioner harm. Additionally, FDA is not aware of evidence, and no data has been submitted in your 510(k), demonstrating that the Pneuview XE is effective in eliminating unsafe negative pressure on the patient. Such promotion of your device for unsupported and uncleared indications may lead to patient harm.\n\nThe Pneuview XE is further misbranded under § 502(a) of the Act, 21 U.S.C. § 352(a), because there are statements on your website and social media sites that, under 21 CFR § 801.6, constitute false or misleading representations with respect to another device. Specifically, the information makes misleading comparisons between your device, a one-way insufflator, and competing devices, two-way insufflators. For example, relevant pictures, illustrations, videos, literature, and written\u002Fverbal statements include the following:\n\n• A picture of smoke venting out of the patient into the OR in the two-way insufflator and a picture showing that all the smoke is vented outside the OR by one-way insufflator on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating, with respect to two-way insufflators, that, “Smoke particulates and some gases are removed however toxic [gas] is vented into the OR” on your website page titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it minimizes the smoke reduction characteristics contained in two-way insufflators.\n\n• Stating that the recirculating system of two-way insufflators “[c]ycles contaminated gases through insufflator potentially increasing the risk of cross contamination and build-up of toxic gas”, under the section on your website titled, “What Technology Is Used In Your OR?” (https:\u002F\u002Fwww.lexionmedical.com\u002Fyouror). This information is misleading in that it fails to recognize that both one-way and two-way systems carry these risks and contain filtration capabilities to mitigate these risks.\n\n• Referencing a limited selection of journal articles about competing devices under the section on your website titled, “Resources”2 (https:\u002F\u002Fwww.lexionmedical.com\u002Finsights) and “Testimonials” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews). This information is misleading in that it may cause medical practitioners to overestimate the type of protection provided to their patients by use of your device in the OR.\n\n• Stating in videos and literature on social media platforms, including YouTube, that there is “constant venting of gas into the atmosphere” which increases the risk of cross-contamination and colonization of pathogens in two-way insufflators and referencing a limited selection of journal articles, as described above. This information is misleading in that it mischaracterizes two-way devices by failing to recognize their smoke reduction characteristics.\n\nWe are not aware of any new data supporting such claims. Such claims are false or misleading because data do not demonstrate that the Pneuview XE is superior to other insufflator devices. These comparisons may mislead consumers about the effectiveness of the Pneuview XE by implying less effectiveness of other devices. Misleading information may lead clinicians to overestimate the performance of the device and minimize the importance of other risk mitigating steps, which may lead to practitioner and patient harm. These claims therefore constitute misleading representations with respect to another device. If you do have data demonstrating that Pneuview XE is more effective than other insufflation devices, please provide that information to the agency.\n\nAdditionally, the FDA has observed that your website currently offers the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE for sale in the United States as being intended to mitigate, prevent, treat, diagnose or cure COVID-193 in people. Promoting these devices as an effective prevention method against COVID-19 constitutes a major change or modification to its intended use, for which your firm lacks clearance or approval, and requires premarket submission prior to marketing. For example, in videos under the sections on your website titled, “COVID-19” (https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19) and “Testimonials,” (https:\u002F\u002Fwww.lexionmedical.com\u002Freviews) several statements are made about how your devices provide safety against COVID-19. Some of those statements include the following:\n\n• The video titled, “How Does Lexion Compare with other Insufflation Systems for COVID-19?” provides a testimonial that states in part:\n\n “This COVID crisis has brought a lot of focus on how we work in the operating room and particularly the risks to us and our patients that could come from some of the laparoscopic insufflation devices [used]…to perform procedures.” (minute 0:23)\n\n In the context of COVID-19, the video goes on to compare two-way systems, and how they remove “a lot of raw gas out of the patient and straight into the room…dumping the gas back into the OR room and the OR atmosphere… [potentially] contaminating the device itself [leading to contamination] into the patient or the next patient.” (minute 2:32) to traditional one-way systems and leakage of gas that “escape[s] through any variety of ways” (minute 2:45)\n\n The video clip then describes the advantages of the AP 50\u002F30 Insufflator which include, “The Lexion is a valved system [that has] minimal spillage of gas out of the port and into the [OR] room during the procedure.” (minute 6:03)\n\n The video concludes that “[a] lot of the different surgical societies have been making recommendations in the midst of this COVID crisis about ways we can try to protect ourselves and those we work with, and … [based on those recommendations] the Lexion AP 50 seems to checks all those boxes for us.” (minute 6:50) [https:\u002F\u002Fwww.lexionmedical.com\u002Fcovid-19].\n\n• In the video titled, “Why this Oncology GYN Robotic Surgeon switched to the Lexion System,” the testimonial states, “…but lately, mainly due to COVID-19… I’m using the system by Lexion which to me is the safest and best system out there… It’s just so much safer with the current climate… I would just hate to have a patient who turns COVID-19 positive.” (minute 0:23)\n\nTaken together, the statements exemplified above imply that traditional one-way insufflators and two-way insufflators potentially contaminate the OR or lead to contamination to other patients, whereas, the AP 50\u002F30 Insufflator and accessories are recommended for and may be used to mitigate and\u002For prevent the spread of COVID-19. FDA is not aware of evidence demonstrating that the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE are effective in the reduction of the spread of COVID-19. If you have data to support these statements, please submit that data to FDA for review.\n\nIn combination with information displayed on your COVID-19 webpage, as well as other areas of your website, as referenced above, where your firm claims that these devices can remove viral particles, these statements and information indicate that the AP 50\u002F30 Insufflator and its accessories are intended for use to protect OR staff or patients against COVID-19. Such promotion of your device for unsupported and uncleared indications may cause medical practitioners to overestimate the type of protection provided them and their patients by use of your device in the OR, which has the potential to lead to patient and practitioner harm.\n\nThere is currently a global outbreak of respiratory disease caused by a novel coronavirus that has been named “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2). The disease caused by the virus has been named “Coronavirus Disease 2019” (COVID-19). On January 31, 2020, the Department of Health and Human Services (HHS) issued a declaration of a public health emergency related to COVID-19 and mobilized the Operating Divisions of HHS.4 In addition, on March 13, 2020, there was a Presidential declaration of a national emergency in response to COVID-19.5 Therefore, FDA is taking urgent measures to protect consumers from certain products that, without approval, clearance, or authorization by FDA, claim to mitigate, prevent, treat, diagnose, or cure COVID-19 in people. As described herein, you sell a product that is intended for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19 in people. We request that you take immediate action to cease the sale of any unapproved, uncleared, and unauthorized product for use in the mitigation, prevention, treatment, diagnosis, or cure of COVID-19.\n\nFor more information about FDA’s regulation of devices used to mitigate, prevent, treat, diagnose, or cure COVID-19; frequently asked questions; and other helpful resources, visit our website at https:\u002F\u002Fwww.fda.gov\u002Fmedical-devices\u002Femergency-situations-medical-devices\u002Fcoronavirus-covid-19-and-medical-devices.\n\nFDA is advising consumers not to purchase or use certain products that have not been approved, cleared, or authorized by FDA and are being misleadingly represented as safe and\u002For effective for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19. Your firm will be added to a published list on FDA's website of firms and websites that have received warning letters from FDA concerning the sale or distribution of COVID-19 related products in violation of the Act. This list can be found at https:\u002F\u002Fwww.fda.gov\u002Fconsumers\u002Fhealth-fraud-scams\u002Ffraudulent-coronavirus-disease-2019-covid-19-products. Once you have taken actions to address the sale of unapproved, uncleared, and unauthorized product(s) for the mitigation, prevention, treatment, diagnosis, or cure of COVID-19, and any appropriate corrective actions have been confirmed by the FDA, the published list will be updated to indicate that your firm has taken such corrective actions.\n\nFor a device requiring premarket approval, the notification required by section 510(k) of the Act, 21 U.S.C. § 360(k), is deemed satisfied when a PMA is pending before the agency. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described at http:\u002F\u002Fwww.fda.gov\u002FMedicalDevices\u002FDeviceRegulationandGuidance\u002FHowtoMarketYourDevice\u002Fdefault.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed.\n\nFDA requests that Lexion Medical LLC immediately cease activities that result in the misbranding or adulteration of the AP 50\u002F30 Insufflator, Insuflow Port, and Pneuview XE, such as the commercial distribution of the device for the uses discussed above.\n\nYour firm should take prompt action to correct the violations addressed in this letter. We advise you to review your websites, product labels, and other labeling and promotional materials to ensure that you are not misleadingly representing your product(s) as safe and\u002For effective for indications outside the cleared indications, including for COVID-19-related uses, for which they have not been approved, cleared, or authorized by FDA and that you do not make claims that adulterate or misbrand the product(s) in violation of the Act. Also, federal agencies may be advised of the issuance of Warning Letters about devices so that they may take this information into account when considering the award of contracts.\n\nNote, there are two response time frames specified. Within 48 hours, please send an email to COVID-19-Task-Force-CDRH@fda.hhs.gov describing the specific steps you have taken to address the COVID-19 related violations. Include an explanation of each step being taken to prevent the recurrence of any violations, as well as copies of related documentation. If you cannot take action to address this matter completely within 48 hours, state the reason for the delay and the time within which you will do so. For all other claims, please notify this office in writing within fifteen business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Please include documentation of any corrections and\u002For corrective actions (which must address systemic problems) your firm has taken. If your firm’s planned corrections and\u002For corrective actions will occur over time, please include a timetable for implementation of those activities. If corrections and\u002For corrective actions cannot be completed within fifteen business days, please state the reason for the delay and the time within which these activities will be completed. Your firm’s responses should be comprehensive and address all violations included in this Warning Letter. This letter notifies you of our concerns and provides you with an opportunity to address them. If you believe that your products are not in violation of the Act, please provide us with your reasoning and any supporting information for our consideration.\n\nYour firm’s response to address all other violations, should be sent to: Food and Drug Administration, Center for Devices and Radiological Health, Office of Regulatory Programs, Division of Regulatory Programs 2: Establishment Support, Regulatory Inspections and Audits Team, White Oak Building 66, Rm 3572, 10903 New Hampshire Ave, Silver Spring, Maryland 20993 or emailed to CDRHWarningLetterResponses@fda.hhs.gov.\n\nPlease refer to the identification numbers CMS 613588 and CPT2001060 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Jason Roberts, Ph.D., Assistant Director for the Gynecological and Surgical Devices Team, at Jason.Roberts@fda.hhs.gov.\n\nFinally, this letter is not meant to be an all-inclusive list of the violations that exist in connection with the product(s) at your firm or in your promotional materials including your website. It is your firm’s responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. Failure to adequately address any violations may result in legal action, including without limitation, seizure and injunction.\n\nSincerely yours,\n\n\u002FS\u002F\n\nCourtney H. Lias, Ph.D.\n\nOffice Director\n\nOHT3: Office of GastroRenal, ObGyn,\n\nGeneral Hospital and Urology Devices\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCC\n\nShelly Amann, Owner\n\nLexion Medical LLC\n\n545 Atwater Circle\n\nSaint Paul, MN 55103\n\nsamann@lexionmedical.com\n\n______________________\n\n1 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n2 While earlier journal articles dated 2009 -2013 cite some cases of subcutaneous emphysema with AirSeal, later articles show no significant difference in subcutaneous emphysema for AirSeal and standard CO2 insufflator. The 2020 Feng et al article even notes a significantly lesser risk of subcutaneous emphysema with the AirSeal at 12mmHg and the transperitoneal approach. Feng TS, Heulitt G, Islam A, Porter JR. Comparison of valve-less and standard insufflation on pneumoperitoneum-related complications in robotic partial nephrectomy: a prospective randomized trial [published online ahead of print, 2020 Jul 6]. J Robot Surg.\n\n3 As explained below, there is currently an outbreak of a respiratory disease named “Coronavirus Disease 2019” (COVID-19).\n\n4 Secretary of Health and Human Services, Determination that a Public Health Emergency Exists (originally issued Jan. 31, 2020, and subsequently renewed), available at https:\u002F\u002Fwww.phe.gov\u002Femergency\u002Fnews\u002Fhealthactions\u002Fphe\u002FPages\u002Fdefault.aspx.\n\n5 Proclamation on Declaring a National Emergency Concerning the Novel Coronavirus Disease (COVID-19) Outbreak (Mar. 13, 2020), available at https:\u002F\u002Ftrumpwhitehouse.archives.gov\u002Fpresidential-actions\u002Fproclamation-declaring-national-emergency-concerning-novel-coronavirus-disease-covid-19-outbreak\u002F.","Lexion Medical LLC","lexion-medical-llc-613588-07262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Flexion-medical-llc-613588-07262021","2026-10-26T08:09:14.12601+00:00","2021-08-03","613588","Patrick Spearman","2026-08-20T02:44:07.37+00:00","2021-07-26",4,{"510k":96,"classification":97,"enforcement":98,"event":99,"event_backfill":100,"pma":101,"warning_letter":102},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]